Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as balicatib (AAE581)
balicatib · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| balicatib (AAE581) | DRUG | - |
Inclusion Criteria: * At least one knee with osteoarthritis with Kellgren-Lawrence grade 3 * Significant osteoarthritis pain in the knee * Presence of at least one of the risk factors: obesity (BMI \> 28), osteoarthritis at other sites, knee effusion, family history of total joint replacement Excl...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Balicatib was studied for the treatment of knee osteoarthritis in adults. It is an investigational small molecule that was evaluated in a Phase 2 clinical trial in patients with osteoarthritis of the knee. It is not an approved therapy.
Balicatib targets cathepsin K, also known as CTSK. It is a small molecule inhibitor of this enzyme. Cathepsin K is a protease involved in the breakdown of collagen in bone and cartilage, which is relevant to joint degeneration in osteoarthritis.
Balicatib was developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 2 clinical trial of balicatib in knee osteoarthritis.
Balicatib reached Phase 2 clinical development. It has not been approved by the FDA and remains an investigational drug. The Phase 2 trial in knee osteoarthritis has been completed.
Balicatib was studied in one completed Phase 2 trial, NCT00371670, titled Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee. The trial enrolled 223 participants across the United States and Germany and was randomized and double blind.
Yes, balicatib is also known as AAE581. Both names refer to the same investigational cathepsin K inhibitor developed by Novartis. The Phase 2 knee osteoarthritis trial used the designation balicatib (AAE581).